GenCore version 5.1.3


OM protein - nucleic search, using frame_plus_p2n model

Run on: January 16, 2003, 15:51:22 ; Search time 229.2 Seconds
(without alignments)
137.557 Million cell updates/sec

Title: US-09-856-070-17
Perfect score: 69
Sequence: 1 EPEKEQMMPEKEEL 14

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Command line parameters:
-MODEL=frame+_p2n.model -DEV-x!p
-Q=/cgn2_1/USPTO_spool/US09856070/runat_14012003_155833_1611/app_query.fasta_1 1542
-DB=N_Geneseq_101002 -QFMT=fastap -SUFFIX=rng -MINMATCH 0.1 -[illegible]
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=pto -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN 2000000000
-USER=US09856070_800N_1_1_448_&runat_14012003_155833_1611 -NCPU=6 -[illegible]
-NO_XLPXY -NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -[illegible] -DEV_TIMEOUT=120
-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6 -FGAPEXT=7
-YGAPOP=10 -YGAPEXT=0.5 -DELOP 6 -DELEXT=7

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|---|
| 1 | | 69 | 100.0 | 2595 | 22 | AAH33385 | Human colon cancer |
| 2 | | 69 | 100.0 | 2930 | 24 | ABQ88182 | Human osteoblast d |
| 3 | | 69 | 100.0 | 2930 | 24 | ABK70285 | Human lung cancer |
| 4 | | 69 | 100.0 | 3044 | 24 | ABQ88180 | Human osteoblast d |
| 5 | | 69 | 100.0 | 3044 | 24 | ABK84552 | Human cDNA differe |
| 6 | | 69 | 100.0 | 3044 | 24 | ABN97223 | Gene #3721 used to |
| 7 | | 69 | 100.0 | 3047 | 24 | ABK09702 | Human ovarian tumo |
| 8 | | 69 | 100.0 | 3072 | 24 | ABQ88182 | Human osteoblast d |
| 9 | | 69 | 100.0 | 3115 | 21 | AAC98113 | Human colon cancer |
| c | 10 | 69 | 100.0 | 11445 | 22 | AAK70537 | Human immune/haema |
| | 11 | 51 | 73.9 | 1815 | 23 | AAS80764 | DNA encoding novel |
| | 12 | 51 | 73.9 | 2979 | 23 | ABV25470 | Human prostate exp |
| | 13 | 51 | 73.9 | 4226 | 23 | AAS84134 | DNA encoding novel |
| | 14 | 51 | 73.9 | 4558 | 22 | AAH72780 | Human cervical can |
| c | 15 | 51 | 73.9 | 149671 | 24 | ABK84797 | Human cDNA differe |
| | 16 | 50 | 72.5 | 80241 | 20 | AAV83943 | HC-contig derived |
| | 17 | 50 | 72.5 | 80595 | 20 | AAV83939 | HC-contig derived |
| c | 18 | 48 | 69.6 | 270 | 14 | AAQ39675 | Expressed Sequence |
| c | 19 | 48 | 69.6 | 270 | 14 | AAQ59087 | Human brain Expres |
| | 20 | 47 | 68.1 | 1773 | 22 | AAI61314 | Human polynucleoti |
| | 21 | 47 | 68.1 | 1773 | 22 | AAI61315 | Human polynucleoti |
| | 22 | 47 | 68.1 | 1831 | 22 | AAS26441 | Human cDNA encodin |
| | 23 | 47 | 68.1 | 2058 | 22 | AAS26006 | Human cDNA encodin |
| | 24 | 47 | 68.1 | 2300 | 21 | AAC76437 | Human ORFX ORF1992 |
| | 25 | 47 | 68.1 | 2956 | 22 | AAS21251 | Human cDNA sequenc |
| | 26 | 47 | 68.1 | 2976 | 22 | AAH18381 | Human cDNA sequenc |
| | 27 | 47 | 68.1 | 2986 | 24 | ABA94364 | Human APRC polypep |
| | 28 | 47 | 68.1 | 3036 | 22 | AAI59528 | Human polynucleoti |
| | 29 | 47 | 68.1 | 3096 | 22 | AAI59529 | Human polynucleoti |
| c | 30 | 47 | 68.1 | 3316 | 23 | ABV23470 | Human prostate exp |
| c | 31 | 47 | 68.1 | 3316 | 23 | ABV29328 | Human prostate exp |
| | 32 | 47 | 68.1 | 3583 | 22 | AAH29907 | C albicans apoptos |
| | 33 | 47 | 68.1 | 7078 | 23 | ABL03681 | Drosophila melanog |
| c | 34 | 47 | 68.1 | 13085 | 23 | ABL03680 | Drosophila melanog |
| | 35 | 47 | 68.1 | 34514 | 22 | AAK78746 | Human immune/haema |
| | 36 | 46 | 66.7 | 225 | 24 | ABN75119 | Human ORF66 cDNA, |
| | 37 | 46 | 66.7 | 2247 | 22 | AAS21266 | Human cDNA sequenc |
| | 38 | 46 | 66.7 | 2381 | 19 | AAV32539 | Human quanylate bi |
| | 39 | 46 | 66.7 | 2428 | 24 | ABL58973 | Human tumour marke |
| | 40 | 46 | 66.7 | 2861 | 23 | ABL10743 | Drosophila melanog |
| c | 41 | 46 | 66.7 | 4155 | 23 | ABL10774 | Drosophila melanog |
| | 42 | 46 | 66.7 | 4454 | 24 | ABN59730 | Novel human coding |
| c | 43 | 46 | 66.7 | 10760 | 23 | ABL10792 | Drosophila melanog |
| | 44 | 45 | 65.2 | 234 | 24 | ABK76220 | Bacillus licheniio |
| c | 45 | 45 | 65.2 | 245 | 21 | AAA31914 | Plant microsatelli |

ALIGNMENTS

RESULT 1
AAH33385
ID AAH33385 standard; cDNA; 2595 BP.
XX
AC AAH33385;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen encoding cDNA SEQ ID NO:441.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma; ss.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.

XX
PF 28-SEP-2000; 2000WO-US26524.
XX
PR 29-SEP-1999; 99US-0157137
PR 03-NOV-1999; 99US-0163280.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX
DR WPI; 2001-235357/24.
DR P-PSDB; AAG73954.
XX
PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT useful for preventing, diagnosing and/or treating colorectal cancers -
XX
PS Claim 1; Page 2539-2540; 9804pp; English.
XX
CC AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC cancer-associated nucleic acid molecules (N) and proteins (P), where
CC the proteins are collectively known as colon cancer antigens. The colon
CC cancer antigens have cytostatic activity and can be used in gene
CC therapy and vaccine production. N and P may be used in the prevention,
CC diagnosis and treatment of diseases associated with inappropriate P
CC expression. For example, N and P may be used to treat disorders
CC associated with decreased expression by rectifying mutations or deletions
CC in a patient's genome that affect the activity of P by expressing
CC inactive proteins or to supplement the patients own production of P.
CC Additionally, N may be used to produce the colon cancer associated Ps,
CC by inserting the nucleic acids into a host cell and culturing the cell
CC to express the proteins. N and P can be used in the prevention, diagnosis
CC and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204
CC and AAB77789 represent sequences used in the exemplification of the
CC present invention.
CC N.B. Pages 666 to 682 and page 7053 of the sequence listing were
CC missing at time of publication, meaning no sequences are present for
CC SEQ ID NO:1027 to 1052, 7921 and 7922.
XX
SQ Sequence 2595 BP; 742 A; 562 C; 714 G; 567 T; 10 other;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 0.014 | Length: | 2595 |
| Score: | 69.00 | Matches: | 14 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 100.00% | Indels: | 0 |
| DB: | 22 | Gaps: | 0 |

US-09-856-070-17 (1-14) x AAH33385 (1-2595)

```
Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||||||||||||||||||||||||||||||||||||||||||||
Db     628 GAGAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 669
```

RESULT 2
ABQ88181
ID ABQ88181 standard; cDNA; 2940 BP.
XX
AC ABQ88181;
XX
DT 18-SEP-2002 (first entry)
XX
DE Human osteoblast differentiation related cDNA SEQ ID NO 88.
XX
KW Human; osteoblast; stem cell differentiation; bone tissue deposition;
KW osteoporosis; osteopathic; ss.
XX
OS Homo sapiens.
XX
PN WO200250301-A2.
XX
PD 27-JUN-2002.
XX
PF 18-DEC-2001; 2001WO-US48276.
XX
PR 18-DEC-2000; 2000US-255882P.
PR 24-APR-2001; 2001US-285691P.
XX
PA (GENE-) GENE LOGIC INC.
PA (PROC ) PROCTER & GAMBLE CO.
XX
PI Ji D, Axelrod DW, Cook JS, Jaiswal N, Einstein R, Houghton A;
PI Mertz L;
XX
DR WPI; 2002-557663/59.
XX
PT Use of genes and their expression profiles associated with osteoblast
PT differentiation for screening modulators bone formation, for diagnosing
PT or treating e.g. osteoporosis, or as markers for the differentiation
PT process -
XX
PS Claim 1; SEQ ID NO 88; 78pp + Sequence Listing; English.
XX
CC The invention relates to genes and their expression profiles are used
CC for:
CC (a) screening modulators of precursor stem cell differentiation into
CC osteoblasts, of bone tissue deposition;
CC (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC osteoblast formation or osteoporosis; or
CC (c) treating or monitoring treatment of the conditions cited in (b), or
CC monitoring the progression of bone tissue deposition.
CC Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC drug-induced abnormalities in bone formation or bone loss, conditions
CC that involve altered bone metabolism (e.g. idiopathic juvenile
CC osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC Fanconi syndrome or fibrous dysplasia. The present sequence is that of an
CC osteoblast differentiation associated cDNA marker of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 2930 BP; 793 A; 658 C; 821 G; 658 T; 0 other;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 0.0161 | Length: | 2930 |
| Score: | 69.00 | Matches: | 14 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 100.00% | Indels: | 0 |
| DB: | 24 | Gaps: | 0 |

US-09-856-070-17 (1-14) x ABQ88181 (1-2930)

```
Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||||||||||||||||||||||||||||||||||||||||||||
Db    1076 GAGAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 1117
```

RESULT 3
ABK70285
ID ABK70285 standard; cDNA; 2930 BP.
XX
AC ABK70285;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human lung cancer associated full length cDNA DMSM-51.
XX
KW Human; ss; gene; lung cancer; cytostatic; tumour; vaccine.
XX
OS Homo sapiens.
XX
PN WO200224057-A2.
XX
PD 28-MAR-2002.
XX

PF 20-SEP-2001; 2001WO-US42232.
XX
PR 22-SEP-2000; 2000US-234837P.
PR 10-OCT-2000; 2000US-239440P.
PR 29-JUN-2001; 2001US-301928P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Benson DR, Mohamath R, Lodes MJ;
XX
DR WPI; 2002-372001/40
XX
PT New tumour lung proteins and nucleic acids encoding the proteins, useful
PT as vaccines and for treating, preventing, diagnosing or monitoring lung
PT cancer -
XX
PS Claim 1; Page 159-163; 189pp; English.
XX
CC The invention relates to an isolated polynucleotide comprising a sequence
CC selected from 183 human DNA sequences (appearing as ABK70130-ABK70312),
CC or their fragments, homologues, variants or complements and their encoded
CC polypeptides. Also included are an expression vector comprising the
CC polynucleotide operably linked to an expression control sequence; a host
CC cell transformed or transfected with an expression vector of; an isolated
CC antibody, or its antigen-binding fragment that specifically binds to the
CC polypeptide, a method for detecting the presence of a cancer in a
CC patient; a fusion protein comprising at least the polypeptide; an
CC oligonucleotide that hybridises to the polynucleotide under moderately
CC stringent conditions, a method for stimulating and/or expanding T cells
CC specific for a tumour protein; an isolated T cell population comprising T
CC cells prepared from the method of above, a composition comprising a first
CC component consisting of carriers and immunostimulants, and a second
CC component selected from the polynucleotides, proteins, antibodies, fusion
CC proteins, T cell populations and antigen presenting cells expressing the
CC polypeptide, methods for stimulating an immune response or treating
CC cancer in a patient by administering the composition and diagnostic kits
CC comprising at least one of the oligonucleotide of, or an antibody and a
CC detection reagent consisting of a reporter group. The polypeptides and
CC polynucleotides are useful as vaccines for the treatment or prevention of
CC lung cancer, and for diagnosis and monitoring of such cancer. The
CC polynucleotide, polypeptide and antigen presenting cells can be
CC used to stimulate or expand T cells specific for a tumorous protein.
CC The polynucleotides may be used as probes or primers for nucleic acid
CC hybridisation, and in the preparation of ribozyme molecules for
CC inhibiting expression of tumour polypeptides and proteins in tumour
CC cells. The present sequence is one of the 183 lung cancer associated
CC polynucleotides.
XX
SQ Sequence 2930 BP; 793 A; 658 C; 821 G; 658 T; 0 other;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 0.0161 | Length: | 2930 |
| Score: | 69.00 | Matches: | 14 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 100.00% | Indels: | 0 |
| DB: | 24 | Gaps: | 0 |

US-09-856-070-17 (1-14) x ABK70285 (1-2930)

```
Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           |||||||||||||| ||||||||||||||||||||||||||||
Db    1076 GAGAGAGAAAGAGCAGATGATGCGGGAGAAGGAGGAGTTG 1117
```

RESULT 4
ABQ88180
ID ABQ88180 standard; cDNA; 3044 BP.
XX
AC ABQ88180;
XX
DT 18-SEP-2002 (first entry)
XX
DE Human osteoblast differentiation related cDNA SEQ ID NO 87.
XX
KW Human; osteoblast; stem cell differentiation; bone tissue deposition;
KW osteoporosis, osteopathic, ss.
XX
OS Homo sapiens.
XX
PN WO200250301-A2.
XX
PD 27-JUN-2002.
XX
PF 18 DEC-2001; 2001WO-US48276.
XX
PR 18-DEC-2000; 2000US-255882P.
PR 24-APR-2001; 2001US-285691P.
XX
PA (GENE-) GENE LOGIC INC.
PA (PROC ) PROCTER & GAMBLE CO.
XX
PI Ji H, Axelrod HW, Cook JS, Jaiswal N, Einstein R, Houghton A,
PI Mertz L;
XX
DR WPI; 2002-557663/59.
XX
PT Use of genes and their expression profiles associated with osteoblast
PT differentiation for screening modulators bone formation, for diagnosing
PT or treating e.g. osteoporosis, or as markers for the differentiation
PT process -
XX
PS Claim 1; SEQ ID NO 87; 78pp + Sequence Listing; English.
XX
CC The invention relates to genes and their expression profiles are used
CC for:
CC (a) screening modulators of precursor stem cell differentiation into
CC osteoblasts, or bone tissue deposition;
CC (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC osteoblast formation or osteoporosis; or
CC (c) treating or monitoring treatment of the conditions cited in (b), or
CC monitoring the progression of bone tissue deposition.
CC Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC drug-induced abnormalities in bone formation or bone loss, conditions
CC that involve altered bone metabolism (e.g. idiopathic juvenile
CC osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC ranconi syndrome or fibrous dysplasia. The present sequence is that of an
CC osteoblast differentiation associated cDNA marker of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 3044 BP; 826 A; 687 C; 855 G; 675 T; 1 other;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 0.0169 | Length: | 3044 |
| Score: | 69.00 | Matches: | 14 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 100.00% | Indels: | 0 |
| DB: | 24 | Gaps: | 0 |

US-09-856-070-17 (1-14) x ABQ88180 (1-3044)

```
Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||||||||||||||||||||||||||||||||||||||||||||
Db    1117 GAGAGAGAAAGAGCAGATGATGCGGGAGAAGGAGGAGTTG 1158
```

RESULT 5
ABK84552
ID ABK84552 standard; cDNA; 3044 BP.
XX
AC ABK84552;
XX
DT 14-AUG-2002 (first entry)
XX

```
DE   Human cDNA differentially expressed in granulocytic cells #1123.
XX
KW   Human; ss; granulocytic cell; DNA chip, bacterial infection,
KW   viral infection; parasitic infection; protozoal infection;
KW   fungal infection, sterile inflammatory disease, psoriasis;
KW   rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW   cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW   adult respiratory distress syndrome; inflammatory bowel disease;
KW   Crohn's disease; ulcerative colitis; periodontal disease;
KW   granulocyte activation; chronic inflammation; allergy.
XX
OS   Homo sapiens.
XX
PN   WO200228999-A2.
XX
PD   11-APR-2002.
XX
PF   03-OCT-2001; 2001WO-US30821.
XX
PR   03-OCT-2000; 2000US-237189P.
XX
PA   (GENE-) GENE LOGIC INC.
XX
PI   Beazer-Barclay Y,  Weissman SM,  Yamaga S,  Vockley J;
XX
DR   WPI; 2002-435328/46.
XX
PT   Detecting granulocyte activation by detecting differential expression
PT   of genes associated with granulocyte activation, which serves as
PT   diagnostic markers that is useful for monitoring disease states and
PT   drug toxicity -
XX
PS   Claim 1; SEQ ID No 1123; 114pp; English.
XX
CC   The invention relates to detecting (M1) granulocyte (GC) activation
CC   (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC   DNA chip analysis as given in the specification and comparing
CC   the expression level to an expression level in an unactivated
CC   GC, where differential expression of Gs is indicative of GCA.
CC   Also included are modulating (M2) GA by contacting GC with an agent
CC   that alters the expression of at least one gene in Gs, (2) screening (M3)
CC   for an agent capable of modulating GCA or an inflammation (especially
CC   chronic) in a tissue, an allergic response in a subject, exposure of a
CC   subject to a pathogen or sterile inflammatory disease using the
CC   gene expression profile, (3) detecting (M4) an inflammation (especially
CC   chronic) in a tissue, an allergic response in a subject, exposure of a
CC   subject to a pathogen or sterile inflammatory disease, by detecting the
CC   level of expression in a sample of the tissue of gene(s) from Gs, where
CC   the level of expression of the gene is indicative of inflammation;
CC   (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC   an allergic response in a subject, exposure of a subject to a pathogen
CC   or sterile inflammatory disease, by contacting a tissue having
CC   inflammation with an agent that modulates the expression of gene(s)
CC   from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC   modulating GA; M3 is useful for screening an agent capable of modulating
CC   GCA preferably in an inflammation in a tissue; M4 is useful for
CC   detecting an inflammation (especially chronic) in a tissue, an allergic
CC   response in a subject, exposure of a subject to a pathogen or sterile
CC   inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC   glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC   reperfusion injury, ARDS, adult respiratory distress syndrome,
CC   inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC   periodontal disease, also bacterial infection, viral infection,
CC   parasitic infection, protozoal infection, fungal infection and M5 is
CC   useful for treating one of the above conditions. The present
CC   sequence represents a gene differentially expressed in granulocytes.
CC   Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 3044 BP; 826 A; 687 C; 855 G; 675 T; 1 other;

     Alignment Scores:
     Pred. No.:                0.0169          Length:          3044
     Score:                    69.00           Matches:         14
     Percent Similarity:       100.00%         Conservative:    0
     Best Local Similarity:    100.00%         Mismatches:      0
     Query Match:              100.00%         Indels:          0
     DB:                       24              Gaps:            0

     US-09-856-070-17 (1-14) x AHK84552 (1-3044)

     Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
                ||||||||||||||||||||||||||||||||||||||||||||
     Db    1117 GAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 1158

     RESULT 6
     ABN97223
     ID   ABN97223 standard; DNA; 3044 BP.
     XX
     AC   ABN97223;
     XX
     DT   13-AUG-2002  (first entry)
     XX
     DE   Gene #3721 used to diagnose liver cancer.
     XX
     KW   Gene; liver cancer; ds; hepatocellular carcinoma; hepatotropic;
     KW   metastatic liver tumour, cytostatic, expression profile; disease state;
     KW   disease progression; drug toxicity; drug efficacy; drug metabolism.
     XX
     OS   Homo sapiens.
     XX
     PN   WO200229103-A2.
     XX
     PD   11 APR 2002.
     XX
     PF   02-OCT-2001; 2001WO-US30589.
     XX
     PR   02-OCT-2000; 2000US-237054P.
     XX
     PA   (GENE-) GENE LOGIC INC.
     XX
     PI   Horne D,  Alvares C,  Peres Da-Silva S,  Vockley JG;
     XX
     DR   WPI; 2002-426119/45.
     XX
     PT   Diagnosing and detecting the progression of liver cancer,
     PT   hepatocellular carcinoma or metastatic liver tumor in a patient,
     PT   involves detecting the level of expression of two or more genes in a
     PT   liver tissue sample -
     XX
     PS   Claim 1; SEQ ID NO 3721; 298pp; English.
     XX
     CC   The invention relates to a novel method for diagnosing and detecting the
     CC   progression of liver cancer, hepatocellular carcinoma or metastatic liver
     CC   tumour in a patient, and differentiating metastatic liver cancer from
     CC   hepatocellular carcinoma in a patient, involving detecting the level of
     CC   expression of two or more genes represented in ABN93503-ABN97455 in a
     CC   tissue sample. The method of the invention has hepatotropic, and
     CC   cytostatic activity. The method is useful for diagnosing and detecting
     CC   the progression of liver cancer, hepatocellular carcinoma and metastatic
     CC   liver carcinoma in a patient. The method is useful for identifying
     CC   expression profiles which serve as useful diagnostic markers as well as
     CC   markers that can be used to monitor disease states, disease progression,
     CC   drug toxicity, drug efficacy and drug metabolism.
     CC   Note: The sequence data for this patent did not form part of the printed
     CC   specification, but was obtained in electronic format directly from WIPO
     CC   at ftp.wipo.int/pub/published_pct_sequences.
     XX
     SQ   Sequence 3044 BP; 826 A; 687 C; 855 G; 675 T; 1 other;

     Alignment Scores:
     Pred. No.:                0.0169          Length:          3044
     Score:                    69.00           Matches:         14
     Percent Similarity:       100.00%         Conservative:    0
```

```
Best Local Similarity:  100.00%        Mismatches:     0
Query Match:            100.00%        Indels:         0
DB:                     24             Gaps:           0

US-09-856-070-17 (1-14) x ABN97223 (1-3044)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||||||||||||||||||||||||||||||||||||||||||||
Db    1117 GAGAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 1158

RESULT 7
ABK09792
ID   ABK09792 standard; cDNA; 3047 BP.
XX
AC   ABK09792;
XX
DT   14-MAR-2002  (first entry)
XX
DE   Human ovarian tumour protein encoding cDNA #325.
XX
KW   Human; ovarian tumour protein; cancer; cytostatic; immunostimulant; ss;
KW   gene therapy; CD4+ T cell; CD8+ T cell; PCR primer.
XX
OS   Homo sapiens.
XX
PN   WO200190154-A2.
XX
PD   29-NOV-2001.
XX
PF   23-MAY-2001; 2001WO-US16895.
XX
PR   24-MAY-2000; 2000US-207107P.
PR   13-JUN-2000; 2000US-211457P.
PR   21-JUN-2000; 2000US-213673P.
PR   03-AUG-2000; 2000US-223288P.
PR   01-MAR-2001; 2001US-272790P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Xu J, Mitcham JL, Harlocker SL, Dillon DC, Secrist H, Lodes MJ;
PI   Algate PA, Fling SP, Mannion J, Benson DR, Carter D;
XX
DR   WPI; 2002-097641/13.
XX
PT   New isolated polynucleotide encoding polypeptide comprising portion of
PT   ovarian tumour protein, useful for detection, diagnosis and therapy of
PT   human ovarian cancer -
XX
PS   Claim 1; Page 269 270; 285pp; English.
XX
CC   The invention relates to an isolated polynucleotide encoding a
CC   polypeptide comprising a portion of an ovarian tumour protein. The
CC   sequences of the invention are useful for stimulating an immune response
CC   and for treating ovarian cancer in a patient. An antigen presenting cell
CC   that expresses the sequences is useful for treating ovarian cancer by
CC   incubating CD4+ and/or CD8+ T cells isolated from a patient. The T cells
CC   can then be proliferated and administered to the patient to inhibit the
CC   development of cancer. The DNA sequences are useful as probes or primers
CC   for nucleic acid hybridisation, to direct expression of a polypeptide in
CC   appropriate host cells. Detecting the presence of a cancer in a patient
CC   involves obtaining a biological sample from the patient, contacting the
CC   biological sample with an agent that binds to the protein, detecting the
CC   amount of protein that binds to the agent, comparing the amount of
CC   protein to a predetermined cut-off value and determining the presence of
CC   cancer. Sequences ABK09464-ABK09802 represent PCR primers and cDNA
CC   molecules encoding ovarian tumour proteins of the invention.
XX
SQ   Sequence 3047 BP; 828 A; 687 C; 856 G; 675 T; 1 other;

Alignment Scores:
Pred. No.:              0.0169         Length:         3047
Score:                  69.00          Matches:        14
Percent Similarity:     100.00%        Conservative:   0
```

```
Best Local Similarity:  100.00%        Mismatches:     0
Query Match:            100.00%        Indels:         0
DB:                     24             Gaps:           0

US-09-856-070-17 (1-14) x ABK09792 (1-3047)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||||||||||||||||||||||||||||||||||||||||||||
Db    1117 GAGAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 1158

RESULT 8
ABQ88182
ID   ABQ88182 standard; cDNA; 3072 BP.
XX
AC   ABQ88182;
XX
DT   18-SEP-2002  (first entry)
XX
DE   Human osteoblast differentiation related cDNA SEQ ID NO 89.
XX
KW   Human; osteoblast; stem cell differentiation; bone tissue deposition;
KW   osteoporosis; osteopathic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200250301-A2.
XX
PD   27-JUN-2002.
XX
PF   18-DEC-2001; 2001WO-US48276.
XX
PR   18-DEC-2000; 2000US-255882P.
PR   24-APR-2001; 2001US-285691P.
XX
PA   (GENE-) GENE LOGIC INC.
PA   (PROC ) PROCTER & GAMBLE CO.
XX
PI   Ji D, Axelrod DW, Cook JS, Jaiswal N, Einstein R, Houghton A;
PI   Mertz L;
XX
DR   WPI; 2002-557663/59.
XX
PT   Use of genes and their expression profiles associated with osteoblast
PT   differentiation for screening modulators bone formation, for diagnosing
PT   or treating e.g. osteoporosis, or as markers for the differentiation
PT   process -
XX
PS   Claim 1; SEQ ID NO 89; 78pp + Sequence Listing; English.
XX
CC   The invention relates to genes and their expression profiles are used
CC   for:
CC   (a) screening modulators of precursor stem cell differentiation into
CC   osteoblasts, or bone tissue deposition;
CC   (b) diagnosing abnormal deposition of bone tissue, abnormal rate of
CC   osteoblast formation or osteoporosis; or
CC   (c) treating or monitoring treatment of the conditions cited in (b), or
CC   monitoring the progression of bone tissue deposition.
CC   Specific conditions include postmenopausal osteoporosis, glucocorticoid
CC   osteoporosis or male osteoporosis, osteopenia, osteodystrophy,
CC   drug induced abnormalities in bone formation or bone loss, conditions
CC   that involve altered bone metabolism (e.g. idiopathic juvenile
CC   osteoporosis), skeletal disease linked to breast cancer, mastocytosis,
CC   Fanconi syndrome or fibrous dysplasia. The present sequence is that of an
CC   osteoblast differentiation associated cDNA marker of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 3072 BP; 846 A; 688 C; 868 G; 670 T; 0 other;

Alignment Scores:
Pred. No.:              0.017          Length:         3072
Score:                  69.00          Matches:        14
```

```
Percent Similarity:     100.00%         Conservative:  0
Best Local Similarity:  100.00%         Mismatches:    0
Query Match:            100.00%         Indels:        0
DB:                     24              Gaps:          0

US-09-856-070-17 (1-14) x AHQ88182 (1-3072)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||||||||||||||||||||||||||||||||||||||||||||
Db    1133 GAGAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 1174

RESULT 9
AAC98113
ID   AAC98113 standard; cDNA; 3115 BP.
XX
AC   AAC98113;
XX
DT   09-MAR-2001  (first entry)
XX
DE   Human colon cancer antigen nucleotide sequence SEQ ID NO:123.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW   immunomodulatory; muscular; gynaecological; gastrointestinal;
KW   nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW   neural disorder; immune system disorder; muscular disorder;
KW   reproductive disorder; gastrointestinal disorder; renal disorder;
KW   infectious disease; cardiovascular disorder; ss
XX
OS   Homo sapiens.
XX
PN   WO200055351-A1
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US05883
XX
PR   12-MAR-1999;  99US-0124270.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA, Ruben SM;
XX
DR   WPI; 2000-587534/55
DR   P-PSDB; AAB53356.
XX
PT   Colon cancer associated gene sequences, referred to as colon cancer
PT   antigens, useful for the treatment, prevention, and diagnosis of colon
PT   disorders such as colon cancer -
XX
PS   Claim 1; Page 559-560; 2104pp; English
XX
CC   AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC   called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC   human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC   neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC   vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC   can be used in gene therapy. The colon cancer antigen polynucleotides,
CC   proteins and antibodies to the proteins are useful for the prevention,
CC   treatment and diagnosis of colon disorders, such as colon cancer. The
CC   polynucleotides may be used in diagnostics and research, such as for
CC   chromosome identification, and as hybridisation probes. The proteins
CC   may also be used to prevent diseases such as neural disorders, immune
CC   system disorders, muscular disorders, reproductive disorders,
CC   gastrointestinal disorders, wounds, renal disorders, infectious
CC   diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC   AAB54007 represent sequences used in the exemplification of the present
CC   invention.
XX
SQ   Sequence 3115 BP; 874 A; 696 C; 872 G; 670 T; 4 other;

Alignment Scores:
Pred. No.:              0.0173          Length:        3115

     Score:                  69.00          Matches:       14
     Percent Similarity:     100.00%        Conservative:  0
     Best Local Similarity:  100.00%        Mismatches:    0
     Query Match:            100.00%        Indels:        0
     DB:                     21             Gaps:          0

     US-09-856-070-17 (1-14) x AAC98113 (1-3115)

     Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
                ||||||||||||||||||||||||||||||||||||||||||||
     Db    1149 GAGAGAGAGAAAGAGCAGATGATGCGCGAGAAGGAGGAGTTG 1190

     RESULT 10
     AAK70537/c
     ID   AAK70537 standard; DNA; 11445 BP.
     XX
     AC   AAK70537;
     XX
     DT   06-NOV-2001  (first entry)
     XX
     DE   Human immune/haematopoietic antigen genomic sequence SEQ ID NO:25349.
     XX
     KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
     KW   cytostatic; gene therapy; vaccine; metastasis; ds.
     XX
     OS   Homo sapiens.
     XX
     PN   WO200157182-A2.
     XX
     PD   09-AUG-2001.
     XX
     PF   17-JAN-2001; 2001WO-US01354.
     XX
     PR   31-JAN-2000; 2000US-0179065.
     PR   04-FEB-2000; 2000US-0180628.
     PR   24-FEB-2000; 2000US-0184664.
     PR   02-MAR-2000; 2000US-0186350.
     PR   16-MAR-2000; 2000US-0189874.
     PR   17-MAR-2000; 2000US-0190076.
     PR   18-APR-2000; 2000US-0198123.
     PR   19-MAY-2000; 2000US-0205515.
     PR   07-JUN-2000; 2000US-0209467.
     PR   28-JUN-2000; 2000US-0214886.
     PR   30-JUN-2000; 2000US-0215135.
     PR   07-JUL-2000; 2000US-0216647.
     PR   07-JUL-2000; 2000US-0216880.
     PR   11-JUL-2000; 2000US-0217487.
     PR   11-JUL-2000; 2000US-0217496.
     PR   14-JUL-2000; 2000US-0218290.
     PR   26-JUL-2000; 2000US-0220963.
     PR   26-JUL-2000; 2000US-0220964.
     PR   14-AUG-2000; 2000US-0224518.
     PR   14-AUG-2000; 2000US-0224519.
     PR   14-AUG-2000; 2000US-0225213.
     PR   14-AUG-2000; 2000US-0225214.
     PR   14-AUG-2000; 2000US-0225266.
     PR   14-AUG-2000; 2000US-0225267.
     PR   14-AUG-2000; 2000US-0225268.
     PR   14-AUG-2000; 2000US-0225270.
     PR   14-AUG-2000; 2000US-0225447.
     PR   14-AUG-2000; 2000US-0225757.
     PR   14-AUG-2000; 2000US-0225758.
     PR   14-AUG-2000; 2000US-0225759.
     PR   18-AUG-2000; 2000US-0226279.
     PR   22-AUG-2000; 2000US-0226681.
     PR   22-AUG-2000; 2000US-0226868.
     PR   22-AUG-2000; 2000US-0227182.
     PR   23-AUG-2000; 2000US-0227009.
     PR   30-AUG-2000; 2000US-0228924.
     PR   01-SEP-2000; 2000US-0229287.
     PR   01-SEP-2000; 2000US-0229343.
     PR   01-SEP-2000; 2000US-0229344.
     PR   01-SEP-2000; 2000US-0229345.
```

PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0233968.
PR 14-SEP-2000; 2000US-0242397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234273.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US 0239937.
PR 20-OCT-2000; 2000US 0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US 0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US 0246532.
PR 08-NOV-2000; 2000US-0246604.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US 0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US 0249244.
PR 17-NOV-2000; 2000US 0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US 0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250390.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0251989.
PR 05-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254997.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM,
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/haematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 25443; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91321. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic related diseases, especially
CC cancers and cancer metastases of haematopoietic derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54952 to AAK54956 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 11445 BP, 2807 A, 3157 C, 2738 G, 2743 T, 0 other;

Alignment Scores.

| | | | |
|---|---|---|---|
| Pred. No.: | 0.0769 | Length: | 11445 |
| Score: | 69.00 | Matches: | 14 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 100.00% | Indels: | 0 |
| DB: | 22 | Gaps: | 0 |

US-09-856-070-17 (1-14) x AAK70537 (1-11445)

Qy 1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
||||||||||||||||||||||||||||||||||||||
Db 5562 GAGAGAGAAAGAGAGATGATGAGGGAGAAGGAGGAGTTG 5575

RESULT 11
AAS80764
ID AAS80764 standard; cDNA; 1815 BP.

```
XX
AC   AAS80764;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #16568.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   24-AUG-2000; 2000US-0649167
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73
DR   P-PSDB; ABG16577.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity
XX
PS   Claim 1; SEQ ID No 16568; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS61197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1815 BP; 701 A; 307 C; 422 G; 385 T; 0 other;

Alignment Scores:
Pred. No.:                12.2          Length:          1815
Score:                    51.00         Matches:         10
Percent Similarity:       92.86%        Conservative:    3
Best Local Similarity:    71.43%        Mismatches:      1
Query Match:              73.91%        Indels:          0
DB:                       23            Gaps:            0

US-09-856-070-17 (1-14) x AAS80764 (1-1815)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||:::|||||||||||:::::   ||||||||||||||||||
Db    1063 GAAAAGGAAAAGGAAAGAATAGAACGTGAAAAGGAAGAGCTA 1104

RESULT 12
ABV25470
ID   ABV25470 standard; cDNA; 2979 BP.
XX
AC   ABV25470;
XX
DT   16-SEP-2002  (first entry)
XX
DE   Human prostate expression marker cDNA 25461.
XX
KW   Human; prostate cancer; cytostatic; carcinogen; pharmacodyanamic marker;
KW   pharmacogenomic marker; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200160860-A2.
XX
PD   23-AUG-2001.
XX
PF   20-FEB-2001; 2001WO-US05171.
XX
PR   17-FEB-2000; 2000US-183319P.
PR   16-MAR-2000; 2000US-189862P.
PR   25-MAY-2000; 2000US-207454P.
PR   09-JUN-2000; 2000US-211314P.
PR   18-JUL-2000; 2000US-219007P.
PR   13-DEC-2000; 2000US-255281P.
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R,  Endege WO,  Monahan JE;
XX
DR   WPI; 2001-662795/76.
XX
PT   Novel isolated nucleic acid molecule associated with cancerous state of
PT   prostate cells and correlating with presence of prostate cancer, useful
PT   for detecting presence of prostate cancer, stage of prostate cancer
XX
PS   Claim 1; Page 5057; 11750pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule (I) comprising
CC   a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62218) of the
CC   specification or its complement. (I) is useful for:
CC   (a) assessing whether a patient is afflicted with prostate cancer;
CC   (b) monitoring the progression of prostate cancer in a patient;
CC   (c) assessing the efficacy of a test compound to inhibit prostate
CC   cancer in a patient;
CC   (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC   in a patient;
CC   (e) selecting a composition for inhibiting prostate cancer in a patient;
CC   (f) assessing the prostate cell carcinogenic potential of a compound;
CC   (g) determining whether prostate cancer has metastasized in a patient;
CC   (h) assessing the aggressiveness or indolence of prostate cancer in a
CC   patient;
CC   (I) is also useful as a pharmacodyanamic or pharmacogenomic marker.
XX
SQ   Sequence 2979 BP; 1035 A; 515 C; 635 G; 787 T; 7 other;

Alignment Scores:
Pred. No.:                21.5          Length:          2979
Score:                    51.00         Matches:         10
Percent Similarity:       92.86%        Conservative:    3
Best Local Similarity:    71.43%        Mismatches:      1
Query Match:              73.91%        Indels:          0
DB:                       23            Gaps:            0

US-09-856-070-17 (1-14) x ABV25470 (1-2979)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           ||:::|||||||||||:::::   ||||||||||||||||||
Db    1134 GAAAAGGAAAAGGAAAGAATAGAACGTGAAAAGGAAGAGCTA 1175

RESULT 13
```

```
AAS84134
ID   AAS84134 standard; cDNA; 4226 BP.
XX
AC   AAS84134;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #19938.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067 A2
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT, Liu C, Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG19947.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity -
XX
PS   Claim 1; SEQ ID No 19938, 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 4226 BP; 1071 A; 1059 C; 1080 G; 1015 T; 1 other;

Alignment Scores:
Pred. No.:                32.1          Length:          4226
Score:                    51.00         Matches:         10
Percent Similarity:       92.86%        Conservative:    3
Best Local Similarity:    71.43%        Mismatches:      1
Query Match:              73.91%        Indels:          0
DB:                       23            Gaps:            0

US-09-856-070-17 (1-14) x AAS84134 (1-4226)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           |||::|||||||||||:::::   |||||||||||||||||
Db    1293 GAGAAGGAGAAAGAGAAGATTGAACGGGAGAAGGAGGAGCTG 1334

RESULT 14
AAH72780
ID   AAH72780 standard; cDNA; 4558 BP.
XX
AC   AAH72780;
XX
DT   19-SEP-2001  (first entry)
XX
DE   Human cervical cancer marker nucleic acid 4054.
XX
KW   Cervical cancer, cytostatic, pre-malignant condition, gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200142467-A2.
XX
PD   14-JUN-2001.
XX
PF   08-DEC-2000; 2000WO-US33312.
XX
PR   08-DEC-1999;   99US-0169681
PR   21-DEC-1999;   99US-0171350.
PR   14-MAR-2000; 2000US-0189315.
PR   12-MAY-2000; 2000US-0203791.
PR   09-JUN-2000; 2000US-0210600
PR   21-JUL-2000; 2000US-0220114
XX
PA   (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI   Schlegel R, Deeds J, Berger A, Zhao X;
XX
DR   WPI; 2001-375006/39
XX
PT   New isolated nucleic acid for diagnosing and treating cervical cancer
PT   and for assessing and detecting compounds for treating the cancer -
XX
PS   Claim 1; Page 847-848; 1051pp; English.
XX
CC   The invention relates to novel genes (AAH68727-AAH73383) associated with
CC   cervical cancer with cytostatic activity. The nucleic acids and encoded
CC   polypeptides are useful: to assess if a patient is afflicted with
CC   cervical cancer or has a pre-malignant condition; to monitor the
CC   progression of cervical cancer or a premalignant condition in a patient;
CC   and to select and/or assess the efficacy of a compound or therapy for
CC   inhibiting cervical cancer in a patient. The nucleic acids may also be
CC   useful for gene therapy.
XX
SQ   Sequence 4558 BP; 1131 A; 1175 C; 1113 G; 1139 T; 0 other;

Alignment Scores:
Pred. No.:                35            Length:          4558
Score:                    51.00         Matches:         10
Percent Similarity:       92.86%        Conservative:    3
Best Local Similarity:    71.43%        Mismatches:      1
Query Match:              73.91%        Indels:          0
DB:                       22            Gaps:            0

US-09-856-070-17 (1-14) x AAH72780 (1-4558)

Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
           |||...|||||||||           |||||||||||||||||
Db    1258 GAGAAGGAGAAAGAGAAGATTGAACGGGAGAAGGAGGAGCTG 1299

RESULT 15
ABK84797/c
ID   ABK84797 standard; cDNA; 149671 BP.
XX
AC   ABK84797;
XX
DT   14-AUG-2002  (first entry)
XX
```

```
DE   Human cDNA differentially expressed in granulocytic cells #1368.
XX
KW   Human; ss; granulocytic cell; DNA chip; bacterial infection;
KW   viral infection; parasitic infection; protozoal infection;
KW   fungal infection, sterile inflammatory disease; psoriasis;
KW   rheumatoid arthritis; glomerulonephritis; asthma; thrombosis;
KW   cardiac reperfusion injury; renal reperfusion injury; ARDS;
KW   adult respiratory distress syndrome; inflammatory bowel disease;
KW   Crohn's disease, ulcerative colitis, periodontal disease,
KW   granulocyte activation; chronic inflammation; allergy.
XX
OS   Homo sapiens.
XX
PN   WO200228999-A2.
XX
PD   11-APR-2002.
XX
PF   03-OCT-2001; 2001WO-US30821.
XX
PR   03-OCT-2000; 2000US-237189P.
XX
PA   (GENE-) GENE LOGIC INC.
XX
PI   Beazer-Barclay Y,  Weissman SM,  Yamaqa S,  Vockley J;
XX
DR   WPI; 2002-435328/46.
XX
PT   Detecting granulocyte activation by detecting differential expression
PT   of genes associated with granulocyte activation, which serves as
PT   diagnostic markers that is useful for monitoring disease states and
PT   drug toxicity -
XX
PS   Claim 1; SEQ ID No 1368; 114pp; English.
XX
CC   The invention relates to detecting (M1) granulocyte (GC) activation
CC   (GCA), by detecting the level of expression of gene(s) (Gs) identified by
CC   DNA chip analysis as given in the specification, and comparing
CC   the expression level to an expression level in an unactivated
CC   GC, where differential expression of Gs is indicative of GCA.
CC   Also included are modulating (M2) GA by contacting GC with an agent
CC   that alters the expression of at least one gene in Gs, (2) screening (M3)
CC   for an agent capable of modulating GCA or an inflammation (especially
CC   chronic) in a tissue, an allergic response in a subject, exposure of a
CC   subject to a pathogen or sterile inflammatory disease using the
CC   gene expression profile; (3) detecting (M4) an inflammation (especially
CC   chronic) in a tissue, an allergic response in a subject, exposure of a
CC   subject to a pathogen or sterile inflammatory disease, by detecting the
CC   level of expression in a sample of the tissue of gene(s) from Gs, where
CC   the level of expression of the gene is indicative of inflammation;
CC   (4) treating (M5) an inflammation (especially chronic) or in a tissue,
CC   an allergic response in a subject, exposure of a subject to a pathogen
CC   or sterile inflammatory disease, by contacting a tissue having
CC   inflammation with an agent that modulates the expression of gene(s)
CC   from Gs in the tissue. M1 is useful for detecting GCA; M2 is useful for
CC   modulating GA; M3 is useful for screening an agent capable of modulating
CC   GCA preferably in an inflammation in a tissue; M4 is useful for
CC   detecting an inflammation (especially chronic) in a tissue, an allergic
CC   response in a subject, exposure of a subject to a pathogen or sterile
CC   inflammatory disease (e.g. psoriasis, rheumatoid arthritis,
CC   glomerulonephritis, asthma, thrombosis, cardiac reperfusion injury, renal
CC   reperfusion injury, ARDS, adult respiratory distress syndrome,
CC   inflammatory bowel disease, Crohn's disease, ulcerative colitis,
CC   periodontal disease; also bacterial infection, viral infection,
CC   parasitic infection, protozoal infection, fungal infection and M5 is
CC   useful for treating one of the above conditions. The present
CC   sequence represents a gene differentially expressed in granulocytes.
CC   Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 149671 BP; 45600 A; 33308 C; 32389 G; 38374 T; 0 other;
```

```
  Alignment Scores:
  Pred. No.:              1.91e+03      Length:          149671
  Score:                  51.00         Matches:         10
  Percent Similarity:     92.86%        Conservative:    3
  Best Local Similarity:  71.43%        Mismatches:      1
  Query Match:            73.91%        Indels:          0
  DB:                     24            Gaps:            0

! US-09-856-070-17 (1-14) x ABK84797 (1-149671)

  Qy       1 GluArgGluLysGluGlnMetMetArgGluLysGluGluLeu 14
             |||:::|||||||||:::::   ||||||||||||||||||
  Db   20201 GAGAAGGAGAAAGAGAATGAACGGGAGAAGGAGGAGCTG 20160


  Search completed: January 16, 2003, 17:19:37
  Job time : 241.325 secs
```